Partnership Aims to Bring HL001, Targeting IPF Progression, Into Trials
Ube Industries and HiLung are teaming up to advance HL001, an experimental therapy to prevent disease progression in idiopathic pulmonary fibrosis (IPF). The companies, both based in Japan, anticipate launching clinical studies of HL001 in people by March 2024. “This most recent agreement solidifies the collaboration between Ube Industries…